Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: Possible therapeutic targets?

Pharmacology and Therapeutics

Volumn 140, Issue 3, 2013, Pages 239-257

  Rochette, Luc ^a   Lorin, Julie ^a   Zeller, Marianne ^a   Guilland, Jean Claude ^a   Lorgis, Luc ^a,b   Cottin, Yves ^a,b   Vergely, Catherine ^a  

^a Laboratoire de Physiopathologie et Pharmacologies Cardio Métaboliques LPPCM   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

ADMA; Cardiovascular disease; Free radicals; NO inhibitors; NO synthases

Indexed keywords

ALISKIREN PLUS VALSARTAN; ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; CALMODULIN; CYANOCOBALAMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; FLUINDOSTATIN; FOLIC ACID; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LOSARTAN; METFORMIN; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PYRIDOXINE; RESVERATROL; RETINOL; ROSUVASTATIN; SAPROPTERIN; SEPIAPTERIN; SPIRONOLACTONE; TETRAHYDROBIOPTERIN; UNINDEXED DRUG;

AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SYNTHESIS; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REPERFUSION INJURY; THERAPY EFFECT; VASCULAR DISEASE;

6-PYRUVOYL TETRAHYDROPTERIN SYNTHASE; 7,8-DIHYDRONEOPTERIN 30 TRIPHOSPHATE; 8-OXOGUANINE DNA GLYCOSYLASE; ACTIVATOR PROTEIN 1; ADMA; AF; AGXT2; ALANINE-GLYOXYLATE AMINOTRANSFERASE 2; ANGIOTENSIN; ANTIOXIDANT RESPONSE ELEMENT; AP-1; APOE-KO; APOLIPOPROTEIN E KNOCKOUT; ARE; ASCH(-); ASCORBATE ANION; ASYMMETRIC DIMETHYLARGININE; AT; ATRIAL FIBRILLATION; BH(3); BH(4); C-JUN N-TERMINAL KINASE; CAAS; CALMODULIN; CAM; CARBONYL REDUCTASE; CARDIOVASCULAR; CARDIOVASCULAR DISEASE; CAT; CATALASES; CATIONIC AMINO ACID TRANSPORTERS; CATIONIC AMINO ACIDS; CATS; CR; CV; DDAHS; DHFR; DHPR; DIABETES MELLITUS; DIHYDROFOLATE REDUCTASE; DIHYDROPTERIDINE REDUCTASE; DIMETHYLAMINES; DIMETHYLARGININE DIMETHYLAMINOHYDROLASES; DM; DMA; DMGV; DNTP; EGFR; ERK; ESTIMATED GLOMERULAR FILTRATION RATE; EXTRACELLULAR SIGNAL-REGULATED KINASE; FAD; FINKEL-BISKIS-JINKINS OSTEOSARCOMA; FLAVIN ADENINE DINUCLEOTIDE; FLAVIN MONONUCLEOTIDE; FMN; FORKHEAD PROTEIN; FOS; FOXO; FREE RADICALS; GLUTATHIONE; GLUTATHIONE PEROXIDASES; GLUTATHIONEPEROXIDASE; GP; GPX; GSH; GTP; GTP CYCLOHYDROLASE 1; GTP-CH; GUANOSINE TRIPHOSPHATE; HEAT SHOCK PROTEIN; HIF; HSP; HYPOXIA-INDUCIBLE FACTOR; JNK; L-ARG; L-ARGININE; L-NMMA; L-NNA; LDL; LEUKOCYTE TELOMERE LENGTH; LOW-DENSITY LIPOPROTEIN; LTL; MALONDIALDEHYDE; MAO; MAPK; MDA; METALLOTHIONEIN; MITOGEN-ACTIVATED PROTEIN KINASE; MONOAMINE OXIDASE; MT; N(G)-MONOMETHYL-L-ARGININE; N-NITRO-L-ARGININE; N-OMEGA-HYDROXY-L-ARGININE; NADPH; NADPH OXIDASE; NEURONAL TRYPTOPHAN HYDROXYLASE; NF-ΚB; NICOTINAMIDE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; NO; NO INHIBITORS; NO SYNTHASES; NOHA; NOX; NRF2; NTPH; NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2; NUCLEAR FACTOR ΚB; OGG1; OS; OXIDATIVE STRESS; PAH; PCD; PEROXYREDOXIN; PHENYLALANINE HYDROXYLASE; PRMT; PROTEIN ARGININE METHYL TRANSFERASE; PRX; PTERIN-4A-CARBINOLAMINE DEHYDRATASE; PTPS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; REDOX FACTOR-1; REF-1; RNS; ROS; S-ADENOSYL-L-HOMOCYSTEINE; S-ADENOSYL-L-METHIONINE; SAH; SAM; SDMA; SEPIAPTERIN REDUCTASE; SIRNAS; SMALL INTERFERING RIBONUCLEIC ACIDS; SOD; SR; SUPEROXIDE DISMUTASE; SYMMETRIC DIMETHYLARGININE; TETRAHYDROBIOPTERIN; TH; THCY; THIOREDOXIN; TOCH; TOCOPHEROL; TOTAL PLASMA HOMOCYSTEINE; TRIHYDROBIOPTERIN RADICAL; TRX; TYROSINE HYDROXYLASE; UA; URIC ACID; Y+L AA; Y+LAT TRANSPORTERS; Α-KETO-Δ-(N(G),N(G)-DIMETHYLGUANIDINO)VALERIC ACID;

ANIMALS; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS;

EID: 84885484473     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.07.004     Document Type: Review

References (199)

1. F. Abbasi, T. Asagmi, J.P. Cooke, C. Lamendola, T. McLaughlin, and G.M. Reaven Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus Am J Cardiol 88 2001 1201 1203
2. S. Abhary, K.P. Burdon, A. Kuot, S. Javadiyan, M.J. Whiting, and N. Kasmeridis Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes PLoS One 5 2010 e9462
3. W.K. Alderton, C.E. Cooper, and R.G. Knowles Nitric oxide synthases: structure, function and inhibition Biochem J 357 2001 593 615
4. N.J. Alp, and K.M. Channon Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease Arterioscler Thromb Vasc Biol 24 2004 413 420
5. S. Altenhofer, P.W. Kleikers, K.A. Radermacher, P. Scheurer, J.J. Rob Hermans, and P. Schiffers The NOX toolbox: validating the role of NADPH oxidases in physiology and disease Cell Mol Life Sci 69 2012 2327 2343
6. K. Andersson, N. Gaudiot, C. Ribiere, M. Elizalde, Y. Giudicelli, and P. Arner A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo Br J Pharmacol 126 1999 1639 1645
7. F. Andreozzi, I. Presta, G.C. Mannino, D. Scarpelli, S. Di Silvestre, and N. Di Pietro A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity PLoS One 7 2012 e36224
8. C. Antoniades, C. Bakogiannis, P. Leeson, T.J. Guzik, M.H. Zhang, and D. Tousoulis Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin- mediated endothelial nitric oxide synthase coupling Circulation 124 2011 335 345
9. C. Antoniades, C. Shirodaria, P. Leeson, A. Antonopoulos, N. Warrick, and T. Van-Assche Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis Eur Heart J 30 2009 1142 1150
10. C. Antoniades, C. Shirodaria, N. Warrick, S. Cai, J. de Bono, and J. Lee 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling Circulation 114 2006 1193 1201
11. C. Aoki, A. Nakano, S. Tanaka, K. Yanagi, S. Ohta, and T. Jojima Fluvastatin upregulates endothelial nitric oxide synthase activity via enhancement of its phosphorylation and expression and via an increase in tetrahydrobiopterin in vascular endothelial cells Int J Cardiol 156 2012 55 61
12. T. Asagami, F. Abbasi, M. Stuelinger, C. Lamendola, T. McLaughlin, and J.P. Cooke Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes Metabolism 51 2002 843 846
13. M.T. Bedford, and S.G. Clarke Protein arginine methylation in mammals: who, what, and why Mol Cell 33 2009 1 13
14. A. Ben Baouali, H. Aube, V. Maupoil, B. Blettery, and L. Rochette Plasma lipid peroxidation in critically ill patients: importance of mechanical ventilation Free Radic Biol Med 16 1994 223 227
15. R.H. Boger Association of asymmetric dimethylarginine and endothelial dysfunction Clin Chem Lab Med 41 2003 1467 1472
16. R.H. Boger, R. Maas, F. Schulze, and E. Schwedhelm Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality - an update on patient populations with a wide range of cardiovascular risk Pharmacol Res 60 2009 481 487
17. R.H. Boger, L.M. Sullivan, E. Schwedhelm, T.J. Wang, R. Maas, and E.J. Benjamin Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community Circulation 119 2009 1592 1600
18. G.A. Bray, S.J. Nielsen, and B.M. Popkin Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity Am J Clin Nutr 79 2004 537 543
19. J. Brittes, M. Lucio, C. Nunes, J.L. Lima, and S. Reis Effects of resveratrol on membrane biophysical properties: relevance for its pharmacological effects Chem Phys Lipids 163 2010 747 754
20. R.C. Candipan, B.Y. Wang, R. Buitrago, P.S. Tsao, and J.P. Cooke Regression or progression. Dependency on vascular nitric oxide Arterioscler Thromb Vasc Biol 16 1996 44 50
21. L.S. Capettini, S.F. Cortes, J.F. Silva, J.I. Alvarez-Leite, and V.S. Lemos Decreased production of neuronal NOS-derived hydrogen peroxide contributes to endothelial dysfunction in atherosclerosis Br J Pharmacol 164 2011 1738 1748
22. A.J. Cardounel, H. Cui, A. Samouilov, W. Johnson, P. Kearns, and A.L. Tsai Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function J Biol Chem 282 2007 879 887
23. A.J. Cardounel, Y. Xia, and J.L. Zweier Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethylarginines in the presence and absence of tetrahydrobiopterin J Biol Chem 280 2005 7540 7549
24. M. Carlstrom, A.E. Persson, E. Larsson, M. Hezel, P.G. Scheffer, and T. Teerlink Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension Cardiovasc Res 89 2011 574 585
25. B. Cha, and E.H. Jho Protein arginine methyltransferases (PRMTs) as therapeutic targets Expert Opin Ther Targets 16 2012 651 664
26. W.S. Cheang, W.T. Wong, X.Y. Tian, Q. Yang, H.K. Lee, and G.W. He Endothelial nitric oxide synthase enhancer reduces oxidative stress and restores endothelial function in db/db mice Cardiovasc Res 92 2011 267 275
27. P.F. Chen, and K.K. Wu Two synthetic peptides corresponding to the proximal heme-binding domain and CD1 domain of human endothelial nitric-oxide synthase inhibit the oxygenase activity by interacting with CaM Arch Biochem Biophys 486 2009 132 140
28. D. Cheng, N. Yadav, R.W. King, M.S. Swanson, E.J. Weinstein, and M.T. Bedford Small molecule regulators of protein arginine methyltransferases J Biol Chem 279 2004 23892 23899
29. J.P. Chin-Dusting, L. Willems, and D.M. Kaye l-arginine transporters in cardiovascular disease: a novel therapeutic target Pharmacol Ther 116 2007 428 436
30. G. Clermont, S. Lecour, C. Vergely, M. Zeller, C. Perrin, and V. Maupoil Direct demonstration of nitric oxide formation in organs of rabbits treated by transdermal glyceryl trinitrate using an in vivo spin trapping technique Fundam Clin Pharmacol 17 2003 709 715
31. Y. Cottin, J.M. Doise, V. Maupoil, M. Tanniere-Zeller, F. Dalloz, and M. Maynadie Plasma iron status and lipid peroxidation following thrombolytic therapy for acute myocardial infarction Fundam Clin Pharmacol 12 1998 236 241
32. M.J. Crabtree, and K.M. Channon Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease Nitric Oxide 25 2011 81 88
33. M.J. Crabtree, C.L. Smith, G. Lam, M.S. Goligorsky, and S.S. Gross Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS Am J Physiol Heart Circ Physiol 294 2008 H1530 H1540
34. S. Daff NO synthase: structures and mechanisms Nitric Oxide 23 2010 1 11
35. M. Davids, A.J. van Hell, M. Visser, R.J. Nijveldt, P.A. van Leeuwen, and T. Teerlink Role of the human erythrocyte in generation and storage of asymmetric dimethylarginine Am J Physiol Heart Circ Physiol 302 2012 H1762 H1770
36. C. Delles, M.P. Schneider, S. John, M. Gekle, and R.E. Schmieder Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension Am J Hypertens 15 2002 590 593
37. P.B. Duell, and M.R. Malinow Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease Curr Opin Lipidol 8 1997 28 34
38. B. Ellger, M.C. Richir, P.A. van Leeuwen, Y. Debaveye, L. Langouche, and I. Vanhorebeek Glycemic control modulates arginine and asymmetrical- dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity Endocrinology 149 2008 3148 3157
39. G.P. Fadini, M. Albiero, S. Vigili de Kreutzenberg, E. Boscaro, R. Cappellari, and M. Marescotti Diabetes impairs stem cell and proangiogenic cell mobilization in humans Diabetes Care 36 4 2013 943 949
40. Y. Feng, M. Li, B. Wang, and Y.G. Zheng Discovery and mechanistic study of a class of protein arginine methylation inhibitors J Med Chem 53 2010 6028 6039
41. B. Fink, S. Dikalov, and N. Fink ESR techniques for the detection of nitric oxide in vivo as an index of endothelial function Pharmacol Rep 58 2006 8 15 (Suppl.)
42. U. Forstermann, and W.C. Sessa Nitric oxide synthases: regulation and function Eur Heart J 33 2012 829 837 (837a-837d)
43. D. Fraccarollo, J.D. Widder, P. Galuppo, T. Thum, D. Tsikas, and M. Hoffmann Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction Circulation 118 2008 818 827
44. S. Frantz, A. Adamek, D. Fraccarollo, J. Tillmanns, J.D. Widder, and C. Dienesch The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury Basic Res Cardiol 104 2009 773 779
45. Y. Fukuda, H. Teragawa, K. Matsuda, T. Yamagata, H. Matsuura, and K. Chayama Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolaemia Heart 87 2002 264 269
46. E.D. Garcin, A.S. Arvai, R.J. Rosenfeld, M.D. Kroeger, B.R. Crane, and G. Andersson Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase Nat Chem Biol 4 2008 700 707
47. J.F. Gielis, J.Y. Lin, K. Wingler, P.E. Van Schil, H.H. Schmidt, and A.L. Moens Pathogenetic role of eNOS uncoupling in cardiopulmonary disorders Free Radic Biol Med 50 2011 765 776
48. A. Goette, M. Hammwohner, A. Bukowska, F. Scalera, J. Martens-Lobenhoffer, and D. Dobrev The impact of rapid atrial pacing on ADMA and endothelial NOS Int J Cardiol 154 2012 141 146
49. E. Gomes, R. Duarte, R.P. Reis, A. Candido, N. Cardim, and M.J. Correia Homocysteine increase after acute myocardial infarction - can it explain the differences between case-control and cohort studies? Rev Port Cardiol 21 2002 575 581
50. C.D. Goonasekera, D.D. Rees, P. Woolard, A. Frend, V. Shah, and M.J. Dillon Nitric oxide synthase inhibitors and hypertension in children and adolescents J Hypertens 15 1997 901 909
51. J. Gruber, S. Schaffer, and B. Halliwell The mitochondrial free radical theory of ageing - where do we stand? Front Biosci 13 2008 6554 6579
52. T.J. Guzik, and D.G. Harrison Vascular NADPH oxidases as drug targets for novel antioxidant strategies Drug Discov Today 11 2006 524 533
53. M.K. Hagensen, P.M. Vanhoutte, and J.F. Bentzon Arterial endothelial cells: still the craftsmen of regenerated endothelium Cardiovasc Res 95 2012 281 289
54. B. Halliwell, and J.M. Gutteridge The definition and measurement of antioxidants in biological systems Free Radic Biol Med 18 1995 125 126
55. S. Hamed, B. Brenner, and A. Roguin Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2 Cardiovasc Res 91 2011 9 15
56. R. Heinke, A. Spannhoff, R. Meier, P. Trojer, I. Bauer, and M. Jung Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors ChemMedChem 4 2009 69 77
57. T. Heitzer, K. Krohn, S. Albers, and T. Meinertz Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus Diabetologia 43 2000 1435 1438
58. S.K. Heo, H.J. Yun, E.K. Noh, and S.D. Park Emodin and rhein inhibit LIGHT-induced monocytes migration by blocking of ROS production Vascul Pharmacol 53 2010 28 37
59. A.D. Hingorani, C.F. Liang, J. Fatibene, A. Lyon, S. Monteith, and A. Parsons A common variant of the endothelial nitric oxide synthase (Glu298 → Asp) is a major risk factor for coronary artery disease in the UK Circulation 100 1999 1515 1520
60. D.P. Holden, J.E. Cartwright, S.S. Nussey, and G.S. Whitley Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine Circulation 108 2003 1575 1580
61. E. Hong, Y. Lim, E. Lee, M. Oh, and D. Kwon Tissue-specific and age-dependent expression of protein arginine methyltransferases (PRMTs) in male rat tissues Biogerontology 13 2012 329 336
62. H. Huang, H. Li, P. Martasek, L.J. Roman, T.L. Poulos, and R.B. Silverman Structure-guided design of selective inhibitors of neuronal nitric oxide synthase J Med Chem 56 7 2013 3024 3032
63. H. Huang, P. Martasek, L.J. Roman, B.S. Masters, and R.B. Silverman N(omega)-nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase J Med Chem 42 1999 3147 3153
64. T. Imanishi, H. Tsujioka, H. Ikejima, A. Kuroi, S. Takarada, and H. Kitabata Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes Hypertension 52 2008 563 572
65. J. Jacobi, R. Maas, N. Cordasic, K. Koch, R.E. Schmieder, and R.H. Boger Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice Am J Physiol Heart Circ Physiol 294 2008 H1058 H1066
66. V. Jaquet, L. Scapozza, R.A. Clark, K.H. Krause, and J.D. Lambeth Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets Antioxid Redox Signal 11 2009 2535 2552
67. D.P. Jones Redefining oxidative stress Antioxid Redox Signal 8 2006 1865 1879
68. D.P. Jones, and Y.M. Go Redox compartmentalization and cellular stress Diabetes Obes Metab 12 Suppl. 2 2010 116 125
69. W.B. Kannel, M. Feinleib, P.M. McNamara, R.J. Garrison, and W.P. Castelli An investigation of coronary heart disease in families. The Framingham offspring study Am J Epidemiol 110 1979 281 290
70. Z.S. Katusic, L.V. d'Uscio, and K.A. Nath Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects Trends Pharmacol Sci 30 2009 48 54
71. T. Kawata, M. Daimon, R. Hasegawa, K. Teramoto, T. Toyoda, and T. Sekine Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus Int J Cardiol 132 2009 286 288
72. J.T. Kielstein, S.M. Bode-Boger, J.C. Frolich, E. Ritz, H. Haller, and D. Fliser Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects Circulation 107 2003 1891 1895
73. J.A. Kim, G.P. Neupane, E.S. Lee, B.S. Jeong, B.C. Park, and P. Thapa NADPH oxidase inhibitors: a patent review Expert Opin Ther Pat 21 2011 1147 1158
74. H.L. Kim, and Y.S. Park Maintenance of cellular tetrahydrobiopterin homeostasis BMB Rep 43 2010 584 592
75. C. Korandji, M. Zeller, J.C. Guilland, B. Collin, B. Lauzier, and P. Sicard Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome Atherosclerosis 214 2011 310 315
76. C. Korandji, M. Zeller, J.C. Guilland, C. Vergely, P. Sicard, and L. Duvillard Asymmetric dimethylarginine (ADMA) and hyperhomocysteinemia in patients with acute myocardial infarction Clin Biochem 40 2007 66 72
77. P. Kotsonis, L.G. Frohlich, C.S. Raman, H. Li, M. Berg, and R. Gerwig Structural basis for pterin antagonism in nitric-oxide synthase. Development of novel 4-oxo-pteridine antagonists of (6R)-5,6,7,8-tetrahydrobiopterin J Biol Chem 276 2001 49133 49141
78. J. Kotthaus, D. Schade, and B. Clement Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): a focus on selectivity over arginase J Enzyme Inhib Med Chem 27 2012 24 28
79. C.D. Krause, Z.H. Yang, Y.S. Kim, J.H. Lee, J.R. Cook, and S. Pestka Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential Pharmacol Ther 113 2007 50 87
80. M.A. Kuliszewski, M.R. Ward, J.W. Kowalewski, A.H. Smith, D.J. Stewart, and M.J. Kutryk A direct comparison of endothelial progenitor cell dysfunction in rat metabolic syndrome and diabetes Atherosclerosis 226 1 2013 58 66
81. N. Kuzkaya, N. Weissmann, D.G. Harrison, and S. Dikalov Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase J Biol Chem 278 2003 22546 22554
82. S. Lecour, V. Maupoil, O. Siri, A. Tabard, and L. Rochette Electron spin resonance detection of nitric oxide generation in major organs from LPS-treated rats J Cardiovasc Pharmacol 33 1999 78 85
83. W.J. Lee, H.C. Ou, W.C. Hsu, M.M. Chou, J.J. Tseng, and S.L. Hsu Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells J Vasc Surg 52 2010 1290 1300
84. J. Leiper, and M. Nandi The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis Nat Rev Drug Discov 10 2011 277 291
85. J. Li, J. Solus, Q. Chen, Y.H. Rho, G. Milne, and C.M. Stein Role of inflammation and oxidative stress in atrial fibrillation Heart Rhythm 7 2010 438 444
86. H. Li, F. Xue, J.M. Kraus II, H. Ji, K.J. Labby, and J. Mataka Cyclopropyl- and methyl-containing inhibitors of neuronal nitric oxide synthase Bioorg Med Chem 21 2013 1333 1343
87. X.P. Li, Y. Zhou, S.P. Zhao, M. Gao, Q.C. Zhou, and Y.S. Li Effect of endogenous estrogen on endothelial function in women with coronary heart disease and its mechanism Clin Chim Acta 339 2004 183 188
88. P. Libby The molecular mechanisms of the thrombotic complications of atherosclerosis J Intern Med 263 2008 517 527
89. K.Y. Lin, A. Ito, T. Asagami, P.S. Tsao, S. Adimoolam, and M. Kimoto Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase Circulation 106 2002 987 992
90. W. Linz, P. Wohlfart, M. Baader, K. Breitschopf, E. Falk, and H.L. Schafer The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats Acta Pharmacol Sin 30 2009 935 946
91. H. Liu, X. Qu, Z. Liang, W. Chen, W. Xia, and Y. Song Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs Biochem Biophys Res Commun 377 2008 884 888
92. F. Liu, X. Zhao, F. Perna, L. Wang, P. Koppikar, and O. Abdel-Wahab JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation Cancer Cell 19 2011 283 294
93. E. Lonn, S. Yusuf, M.J. Arnold, P. Sheridan, J. Pogue, and M. Micks Homocysteine lowering with folic acid and B vitamins in vascular disease N Engl J Med 354 2006 1567 1577
94. A. Lopez, J.A. Lorente, J. Steingrub, J. Bakker, A. McLuckie, and S. Willatts Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock Crit Care Med 32 2004 21 30
95. L. Lorgis, M. Zeller, G. Dentan, P. Sicard, C. Richard, and P. Buffet The free oxygen radicals test (FORT) to assess circulating oxidative stress in patients with acute myocardial infarction Atherosclerosis 213 2010 616 621
96. Z. Luo, T. Teerlink, K. Griendling, S. Aslam, W.J. Welch, and C.S. Wilcox Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells Hypertension 56 2010 498 504
97. J.M. Luther, and N.J. Brown The renin-angiotensin-aldosterone system and glucose homeostasis Trends Pharmacol Sci 32 2011 734 739
98. M.L. Marcovecchio, B. Widmer, D.B. Dunger, and R.N. Dalton Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with Type 1 diabetes Clin Sci (Lond) 115 2008 361 369
99. J.D. Martell, H. Li, T. Doukov, P. Martasek, L.J. Roman, and M. Soltis Heme-coordinating inhibitors of neuronal nitric oxide synthase. Iron-thioether coordination is stabilized by hydrophobic contacts without increased inhibitor potency J Am Chem Soc 132 2010 798 806
100. C. Martin, H. Dubouchaud, L. Mosoni, J.M. Chardigny, A. Oudot, and E. Fontaine Abnormalities of mitochondrial functioning can partly explain the metabolic disorders encountered in sarcopenic gastrocnemius Aging Cell 6 2007 165 177
101. J. Martinez-Gonzalez, B. Raposo, C. Rodriguez, and L. Badimon 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation Arterioscler Thromb Vasc Biol 21 2001 804 809
102. H. Masuda, M. Goto, S. Tamaoki, and H. Azuma Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia Br J Pharmacol 126 1999 211 218
103. S. Matetzky, D. Freimark, S. Ben-Ami, I. Goldenberg, J. Leor, and R. Doolman Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction Arch Intern Med 163 2003 1933 1937
104. H. Matter, and P. Kotsonis Biology and chemistry of the inhibition of nitric oxide synthases by pteridine-derivatives as therapeutic agents Med Res Rev 24 2004 662 684
105. T. Michel, and P.M. Vanhoutte Cellular signaling and NO production Pflugers Arch 459 2010 807 816
106. T. Miura, S. Muraoka, N. Ikeda, M. Watanabe, and Y. Fujimoto Antioxidative and prooxidative action of stilbene derivatives Pharmacol Toxicol 86 2000 203 208
107. H. Miyazaki, H. Matsuoka, J.P. Cooke, M. Usui, S. Ueda, and S. Okuda Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis Circulation 99 1999 1141 1146
108. A.L. Moens, E.A. Ketner, E. Takimoto, T.S. Schmidt, C.A. O'Neill, and M.S. Wolin Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure J Mol Cell Cardiol 51 2011 564 569
109. A.L. Moens, E. Takimoto, C.G. Tocchetti, K. Chakir, D. Bedja, and G. Cormaci Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy Circulation 117 2008 2626 2636
110. A.C. Montezano, and R.M. Touyz Reactive oxygen species and endothelial function - role of nitric oxide synthase uncoupling and Nox family nicotinamide adenine dinucleotide phosphate oxidases Basic Clin Pharmacol Toxicol 110 2012 87 94
111. E. Mori, N. Haramaki, H. Ikeda, and T. Imaizumi Intra-coronary administration of l-arginine aggravates myocardial stunning through production of peroxynitrite in dogs Cardiovasc Res 40 1998 113 123
112. K.M. Naseem The role of nitric oxide in cardiovascular diseases Mol Aspects Med 26 2005 33 65
113. S.F. Nunes, I.V. Figueiredo, J.S. Pereira, E.T. de Lemos, F. Reis, and F. Teixeira Monoamine oxidase and semicarbazide-sensitive amine oxidase kinetic analysis in mesenteric arteries of patients with type 2 diabetes Physiol Res 60 2011 309 315
114. M.L. Onozato, A. Tojo, J. Leiper, T. Fujita, F. Palm, and C.S. Wilcox Expression of NG, NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers Diabetes 57 2008 172 180
115. M. Oron-Herman, Y. Kamari, E. Grossman, G. Yeger, E. Peleg, and Z. Shabtay Metabolic syndrome: comparison of the two commonly used animal models Am J Hypertens 21 2008 1018 1022
116. A. Oudot, C. Martin, D. Busseuil, C. Vergely, L. Demaison, and L. Rochette NADPH oxidases are in part responsible for increased cardiovascular superoxide production during aging Free Radic Biol Med 40 2006 2214 2222
117. R. Pabla, and M.J. Curtis Nitric oxide fails to confer endogenous antiarrhythmic cardioprotection in the primate heart in vitro Br J Pharmacol 150 2007 893 898
118. F. Padilla, D. Garcia-Dorado, L. Agullo, J. Inserte, A. Paniagua, and S. Mirabet l-arginine administration prevents reperfusion-induced cardiomyocyte hypercontracture and reduces infarct size in the pig Cardiovasc Res 46 2000 412 420
119. H. Paiva, T. Lehtimaki, J. Laakso, I. Ruokonen, V. Rantalaiho, and O. Wirta Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy Metabolism 52 2003 303 307
120. S. Pal, R.A. Baiocchi, J.C. Byrd, M.R. Grever, S.T. Jacob, and S. Sif Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma EMBO J 26 2007 3558 3569
121. F. Palm, M.L. Onozato, Z. Luo, and C.S. Wilcox Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems Am J Physiol Heart Circ Physiol 293 2007 H3227 H3245
122. I. Palomo, A. Contreras, L.M. Alarcon, E. Leiva, L. Guzman, and V. Mujica Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome Nitric Oxide 24 2011 224 228
123. R.V. Parry, and S.G. Ward Protein arginine methylation: a new handle on T lymphocytes? Trends Immunol 31 2010 164 169
124. A.F. Pasini, U. Garbin, C. Stranieri, V. Boccioletti, C. Mozzini, and S. Manfro Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients Am J Hypertens 21 2008 1251 1257
125. I. Paterniti, M. Galuppo, E. Mazzon, D. Impellizzeri, E. Esposito, and P. Bramanti Protective effects of apocynin, an inhibitor of NADPH oxidase activity, in splanchnic artery occlusion and reperfusion J Leukoc Biol 88 2010 993 1003
126. X. Pi, and C. Patterson Twin layers of lightning: a new role for the chaperone Hsp90 in angiogenesis Arterioscler Thromb Vasc Biol 28 2008 6 7
127. A.J. Pope, K. Karuppiah, and A.J. Cardounel Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production Pharmacol Res 60 2009 461 465
128. S. Puntarulo Iron, oxidative stress and human health Mol Aspects Med 26 2005 299 312
129. G.M. Reaven Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease J Clin Endocrinol Metab 88 2003 2399 2403
130. D.D. Rees, R.M. Palmer, R. Schulz, H.F. Hodson, and S. Moncada Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo Br J Pharmacol 101 1990 746 752
131. C. Richard, B. Lauzier, S. Delemasure, S. Talbot, S. Ghibu, and B. Collin Effects of angiotensin-1 converting enzyme inhibition on oxidative stress and bradykinin receptor expression during doxorubicin-induced cardiomyopathy in rats J Cardiovasc Pharmacol 52 2008 278 285
132. L. Rochette, Y. Cottin, M. Zeller, and C. Vergely Carbon monoxide: mechanisms of action and potential clinical implications Pharmacol Ther 137 2013 133 152
133. L. Rochette, E. Tatou, V. Maupoil, M. Zeller, Y. Cottin, and S. Jazayeri Atrial and vascular oxidative stress in patients with heart failure Cell Physiol Biochem 27 2011 497 502
134. L. Rochette, and C. Vergely Forgotten radicals in biology Int J Biomed Sci 4 2008 255 259
135. N.D. Roe, and J. Ren Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases Vascul Pharmacol 57 2012 168 172
136. J.R. Roede, Y.M. Go, and D.P. Jones Redox equivalents and mitochondrial bioenergetics Methods Mol Biol 810 2012 249 280
137. L.J. Roman, and B.S. Masters Electron transfer by neuronal nitric-oxide synthase is regulated by concerted interaction of calmodulin and two intrinsic regulatory elements J Biol Chem 281 2006 23111 23118
138. S. Rossiter, C.L. Smith, M. Malaki, M. Nandi, H. Gill, and J.M. Leiper Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase J Med Chem 48 2005 4670 4678
139. S. Saliques, J.R. Teyssier, C. Vergely, L. Lorgis, J. Lorin, and M. Farnier Circulating leukocyte telomere length and oxidative stress: a new target for statin therapy Atherosclerosis 219 2011 753 760
140. L.K. Sarna, N. Wu, S.Y. Hwang, Y.L. Siow, and K. O Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages Can J Physiol Pharmacol 88 2010 369 378
141. C. Sartori, and U. Scherrer Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation J Hypertens 17 1999 1517 1525
142. C.L. Sartorio, D. Fraccarollo, P. Galuppo, M. Leutke, G. Ertl, and I. Stefanon Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction Hypertension 50 2007 919 925
143. Y. Sato, T. Ito, N. Udaka, M. Kanisawa, Y. Noguchi, and S.W. Cushman Immunohistochemical localization of facilitated-diffusion glucose transporters in rat pancreatic islets Tissue Cell 28 1996 637 643
144. M. Satoh, S. Fujimoto, S. Arakawa, T. Yada, T. Namikoshi, and Y. Haruna Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy Nephrol Dial Transplant 23 2008 3806 3813
145. M. Satoh, S. Fujimoto, Y. Haruna, S. Arakawa, H. Horike, and N. Komai NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy Am J Physiol Renal Physiol 288 2005 F1144 F1152
146. D. Schade, J. Kotthaus, and B. Clement Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease Pharmacol Ther 126 2010 279 300
147. K. Schmidt, A. Neubauer, B. Kolesnik, J.P. Stasch, E.R. Werner, and A.C. Gorren Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation Mol Pharmacol 82 2012 420 427
148. R. Schnabel, S. Blankenberg, E. Lubos, K.J. Lackner, H.J. Rupprecht, and C. Espinola-Klein Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study Circ Res 97 2005 e53 e59
149. A. Schramm, P. Matusik, G. Osmenda, and T.J. Guzik Targeting NADPH oxidases in vascular pharmacology Vascul Pharmacol 56 2012 216 231
150. S.P. Schulman, L.C. Becker, D.A. Kass, H.C. Champion, M.L. Terrin, and S. Forman l-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial JAMA 295 2006 58 64
151. E. Schulz, T. Jansen, P. Wenzel, A. Daiber, and T. Munzel Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension Antioxid Redox Signal 10 2008 1115 1126
152. C.D. Searles The nitric oxide pathway and oxidative stress in heart failure Congest Heart Fail 8 142-147 2002 155
153. S. Selemidis, C.G. Sobey, K. Wingler, H.H. Schmidt, and G.R. Drummond NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition Pharmacol Ther 120 2008 254 291
154. S. Shimizu, T. Hiroi, M. Ishii, T. Hagiwara, T. Wajima, and A. Miyazaki Hydrogen peroxide stimulates tetrahydrobiopterin synthesis through activation of the Jak2 tyrosine kinase pathway in vascular endothelial cells Int J Biochem Cell Biol 40 2008 755 765
155. P. Sicard, S. Delemasure, C. Korandji, A. Segueira-Le Grand, B. Lauzier, and J.C. Guilland Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats Free Radic Res 42 2008 226 236
156. M.P. Siroen, T. Teerlink, R.J. Nijveldt, H.A. Prins, M.C. Richir, and P.A. van Leeuwen The clinical significance of asymmetric dimethylarginine Annu Rev Nutr 26 2006 203 228
157. M.C. Stuhlinger, P.S. Tsao, J.H. Her, M. Kimoto, R.F. Balint, and J.P. Cooke Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine Circulation 104 2001 2569 2575
158. Q.A. Sun, D.T. Hess, B. Wang, M. Miyagi, and J.S. Stamler Off-target thiol alkylation by the NADPH oxidase inhibitor 3-benzyl-7-(2-benzoxazolyl)thio- 1,2,3-triazolo[4,5-d]pyrimidine (VAS2870) Free Radic Biol Med 52 2012 1897 1902
159. U. Svajger, and M. Jeras Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases Int Rev Immunol 31 2012 202 222
160. T. Teerlink ADMA metabolism and clearance Vasc Med 10 Suppl. 1 2005 S73 S81
161. T. Teerlink, Z. Luo, F. Palm, and C.S. Wilcox Cellular ADMA: regulation and action Pharmacol Res 60 2009 448 460
162. T. Teerlink, R.J. Nijveldt, S. de Jong, and P.A. van Leeuwen Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography Anal Biochem 303 2002 131 137
163. D.D. Thomas, L.A. Ridnour, J.S. Isenberg, W. Flores-Santana, C.H. Switzer, and S. Donzelli The chemical biology of nitric oxide: implications in cellular signaling Free Radic Biol Med 45 2008 18 31
164. T. Thum, D. Fraccarollo, M. Schultheiss, S. Froese, P. Galuppo, and J.D. Widder Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes Diabetes 56 2007 666 674
165. S. Toyokuni Molecular mechanisms of oxidative stress-induced carcinogenesis: from epidemiology to oxygenomics IUBMB Life 60 2008 441 447
166. B. Turan, E. Tuncay, and G. Vassort Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies J Bioenerg Biomembr 44 2012 281 296
167. S. Ueda, S. Kato, H. Matsuoka, M. Kimoto, S. Okuda, and M. Morimatsu Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase Circ Res 92 2003 226 233
168. J.Y. Uriu-Adams, and C.L. Keen Copper, oxidative stress, and human health Mol Aspects Med 26 2005 268 298
169. M. Ushio-Fukai, A.M. Zafari, T. Fukui, N. Ishizaka, and K.K. Griendling p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells J Biol Chem 271 1996 23317 23321
170. V.P. Valkonen, H. Paiva, J.T. Salonen, T.A. Lakka, T. Lehtimaki, and J. Laakso Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine Lancet 358 2001 2127 2128
171. P. Vallance, and J. Leiper Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway Arterioscler Thromb Vasc Biol 24 2004 1023 1030
172. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure Lancet 339 1992 572 575
173. C. Vergely, V. Maupoil, M. Benderitter, and L. Rochette Influence of the severity of myocardial ischemia on the intensity of ascorbyl free radical release and on post-ischemic recovery during reperfusion Free Radic Biol Med 24 1998 470 479
174. C. Vergely, V. Maupoil, G. Clermont, A. Bril, and L. Rochette Identification and quantification of free radicals during myocardial ischemia and reperfusion using electron paramagnetic resonance spectroscopy Arch Biochem Biophys 420 2003 209 216
175. C. Vergely, C. Perrin-Sarrado, G. Clermont, and L. Rochette Postischemic recovery and oxidative stress are independent of nitric-oxide synthases modulation in isolated rat heart J Pharmacol Exp Ther 303 2002 149 157
176. C. Vergely, A. Tabard, V. Maupoil, and L. Rochette Isolated perfused rat hearts release secondary free radicals during ischemia reperfusion injury. Cardiovascular effect of the spin trap alpha-phenyl N-tert-butylnitrone Free Radic Res 35 2001 475 489
177. A. Virdis, M.F. Neves, F. Amiri, E. Viel, R.M. Touyz, and E.L. Schiffrin Spironolactone improves angiotensin-induced vascular changes and oxidative stress Hypertension 40 2002 504 510
178. J. Vitecek, A. Lojek, G. Valacchi, and L. Kubala Arginine-based inhibitors of nitric oxide synthase: therapeutic potential and challenges Mediators Inflamm 2012 2012 318087
179. C. Wadham, and A.A. Mangoni Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease Expert Opin Drug Metab Toxicol 5 2009 303 319
180. J. Wang, L. Chen, S.H. Sinha, Z. Liang, H. Chai, and S. Muniyan Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation J Med Chem 55 2012 7978 7987
181. D. Wang, S. Strandgaard, J. Iversen, and C.S. Wilcox Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension Am J Physiol Regul Integr Comp Physiol 296 2009 R195 R200
182. E.R. Werner, N. Blau, and B. Thony Tetrahydrobiopterin: biochemistry and pathophysiology Biochem J 438 2011 397 414
183. C.S. Wilcox Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables Hypertension 59 2012 375 381
184. G. Williams, X. Shi-Wen, D. Abraham, S. Selvakumar, D.M. Baker, and J.C. Tsui Nitric oxide manipulation: a therapeutic target for peripheral arterial disease? Cardiol Res Pract 2012 2012 656247
185. P. Wohlfart, H. Xu, A. Endlich, A. Habermeier, E.I. Closs, and T. Hubschle Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling J Pharmacol Exp Ther 325 2008 370 379
186. G. Wu, and S.M. Morris Jr. Arginine metabolism: nitric oxide and beyond Biochem J 336 Pt 1 1998 1 17
187. C. Wunderlich, K. Schober, A. Schmeisser, C. Heerwagen, A.K. Tausche, and N. Steinbronn The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium J Mol Cell Cardiol 44 2008 938 947
188. N. Xia, A. Daiber, A. Habermeier, E.I. Closs, T. Thum, and G. Spanier Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice J Pharmacol Exp Ther 335 2010 149 154
189. J. Xu, Y. Wu, P. Song, M. Zhang, S. Wang, and M.H. Zou Proteasome-dependent degradation of guanosine 5′-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus Circulation 116 2007 944 953
190. F. Xue, J. Fang, S.L. Delker, H. Li, P. Martasek, and L.J. Roman Symmetric double-headed aminopyridines, a novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase J Med Chem 54 2011 2039 2048
191. J. Yan, G. Tie, and L.M. Messina Tetrahydrobiopterin, l-arginine and vitamin C actsynergistically to decrease oxidative stress, increase nitricoxide and improve blood flow after induction of hindlimb ischemia in the rat Mol Med 18 2012 676 684
192. Q. Yang, H.M. Xue, W.T. Wong, X.Y. Tian, Y. Huang, and S.K. Tsui AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats Br J Pharmacol 163 2011 1078 1085
193. M. Yoshimatsu, G. Toyokawa, S. Hayami, M. Unoki, T. Tsunoda, and H.I. Field Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers Int J Cancer 128 2011 562 573
194. J.M. Yost, I. Korboukh, F. Liu, C. Gao, and J. Jin Targets in epigenetics: inhibiting the methyl writers of the histone code Curr Chem Genomics 5 2011 72 84
195. J. Yu, M. Weiwer, R.J. Linhardt, and J.S. Dordick The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases Curr Vasc Pharmacol 6 2008 204 217
196. M.N. Zairis, N.G. Patsourakos, G.Z. Tsiaousis, A. Theodossis Georgilas, A. Melidonis, and S.S. Makrygiannis Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure Heart 98 2012 860 864
197. M. Zeller, C. Korandji, J.C. Guilland, P. Sicard, C. Vergely, and L. Lorgis Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction Arterioscler Thromb Vasc Biol 28 2008 954 960
198. Y.H. Zhang, and B. Casadei Sub-cellular targeting of constitutive NOS in health and disease J Mol Cell Cardiol 52 2012 341 350
199. L. Zhang, F. Rao, K. Zhang, S. Khandrika, M. Das, and S.M. Vaingankar Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk J Clin Invest 117 2007 2658 2671